Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Gumarontinib by Shanghai Haihe Biopharma for Non-Small Cell Lung Cancer: Likelihood of Approval
Gumarontinib is under clinical development by Shanghai Haihe Biopharma and currently in Phase II for Non-Small Cell Lung Cancer. According...
HH-2853 by Shanghai Haihe Biopharma for Soft Tissue Sarcoma: Likelihood of Approval
HH-2853 is under clinical development by Shanghai Haihe Biopharma and currently in Phase II for Soft Tissue Sarcoma. According to...
HHCYH-33 by Shanghai Haihe Biopharma for Solid Tumor: Likelihood of Approval
HHCYH-33 is under clinical development by Shanghai Haihe Biopharma and currently in Phase I for Solid Tumor. According to GlobalData,...
HHCYH-33 by Shanghai Haihe Biopharma for Ovarian Cancer: Likelihood of Approval
HHCYH-33 is under clinical development by Shanghai Haihe Biopharma and currently in Phase I for Ovarian Cancer. According to GlobalData,...
HHCYH-33 by Shanghai Haihe Biopharma for Prostate Cancer: Likelihood of Approval
HHCYH-33 is under clinical development by Shanghai Haihe Biopharma and currently in Phase I for Prostate Cancer. According to GlobalData,...
HHCYH-33 by Shanghai Haihe Biopharma for Endometrial Cancer: Likelihood of Approval
HHCYH-33 is under clinical development by Shanghai Haihe Biopharma and currently in Phase I for Endometrial Cancer. According to GlobalData,...
HHCYH-33 by Shanghai Haihe Biopharma for Breast Cancer: Likelihood of Approval
HHCYH-33 is under clinical development by Shanghai Haihe Biopharma and currently in Phase I for Breast Cancer. According to GlobalData,...
HH-2853 by Shanghai Haihe Biopharma for Sarcomas: Likelihood of Approval
HH-2853 is under clinical development by Shanghai Haihe Biopharma and currently in Phase II for Sarcomas. According to GlobalData, Phase...